[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-lymphocytic-leukemia-cll\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-lymphocytic-leukemia-cll":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,49,77,108,138,169,197,233,256,282,304,328,357,382,409,428,447,473,504,531,558,569,595,622,633],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053355","study-of-the-use-of-venetoclax-in-participants-with-chronic-lymphocytic-leukemia-cll-under-real-life-setting-100053355",false,"NCT03342144","Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting","Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland","VeRVe","Inclusion Criteria:\n\n\\- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.\n\nExclusion Criteria:\n\n\\- None","ALL","18 Years",{"count":21,"type":22},500,"ESTIMATED","OBSERVATIONAL","An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.",[26],"Chronic Lymphocytic Leukemia (CLL)",[26,28,29,30,31,32,33,34,35],"Cancer","Leukemia","venetoclax","rituximab","obinutuzumab","ABT-199","venclexta","venclyxto","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2017-12-04",{"date":44,"type":22},"2030-12",{"name":46,"class":47},"AbbVie","INDUSTRY",70,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100053791","registry-platform-hematologic-malignancies-rubin---extension-of-tumor-registry-lymphatic-neoplasms-100053791","NCT06043011","Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms","Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms","RUBIN","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Confirmed diagnosis of the respective NHL\n* If patient is alive: signed written informed consent\n\n  * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.\n  * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.\n\nExclusion Criteria:\n\n* No systemic therapy for respective lymphoid malignancy.",{"count":58,"type":22},2950,"5 Years","The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.",[26,62,63,64,65,66],"Diffuse Large B-cell Lymphoma (DLBCL)","Follicular Lymphoma (FL)","Mantle Cell Lymphoma (MCL)","Marginal Zone Lymphoma (MZL)","Waldenström's Macroglobulinemia (WM)",[68],"non-Hodgkin lymphoma (NHL)",{"date":39,"type":40},{"date":71,"type":40},"2023-09-27",{"date":73,"type":22},"2033-12",{"name":75,"class":47},"iOMEDICO AG",1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100594842","phase-2-phase-2-study-of-disease-risk-mutation-guided-finite-acalabrutinibvenetoclax-for-relapsed-cll-post-1l-finite-cbtkibcl2i--obinutuzumab-100594842","NCT07024706","Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL\u002FSLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab","MAVRiC","Main Inclusion Criteria:\n\n1. Participant must be ≥ 18 years at the time of signing informed consent.\n2. Diagnosis of CLL\u002FSLL according to iwCLL guidelines 2018 (Hallek et al. 2018)\n3. Participants must have received first line treatment with fixed duration covalent BTKi plus BCL2i therapy (± obinutuzumab) with a response ≥ PR (i.e., CR, CRi, nPR, or PR) with a minimum of 2 years since the end of the prior 1L treatment.\n4. The following data must be available or at least the appropriate samples drawn\u002Facquired prior to dosing:\n\n   1. IGHV (mutated vs. unmutated)\n   2. del(17p) (present or absent)\n   3. TP53 mutation (present or absent)\n5. ECOG performance status 0, 1 or 2\n6. Adequate organ and bone marrow (BM) function.\n\nMain Exclusion Criteria:\n\n1. Any evidence of diseases that, in the investigator's opinion, makes it undesirable for patient to participate in the study.\n2. Significant cardiovascular or cerebrovascular disease.\n3. Active bleeding or history of bleeding diathesis (e.g., hemophilia or von Willebrand disease).\n4. Child-Pugh B\u002FC liver cirrhosis.\n5. History of prior or current malignancy.\n6. HIV positive\n7. History of progressive multifocal leukoencephalopathy (PML).\n8. Active hepatitis B or C infection:\n9. Corticosteroid use \\> 20 mg within 1 week before the first dose of study intervention.\n10. History of hypersensitivity or anaphylaxis to study intervention(s).\n11. Requires treatment with a strong CYP3A4 inhibitor\u002Finducer.\n12. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists.\n13. Major surgical procedure within 30 days of the first dose of study intervention.","130 Years",{"count":87,"type":22},80,"INTERVENTIONAL",[90],"PHASE2","This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.",[26,93],"Small Lymphocytic Lymphoma (SLL)",[26,93,95,96,97],"Relapsed CLL","Refractory CLL","Acalabrutinib","2026-07-01",{"date":100,"type":40},"2026-07-02",{"date":102,"type":40},"2026-06-04",{"date":104,"type":22},"2033-03-23",{"name":106,"class":47},"AstraZeneca",36,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":117,"conditions":118,"keywords":124,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":76},"100494895","observational-study-of-cardiac-arrhythmias-during-treatment-with-btk-inhibitors-or-venetoclax-100494895","NCT05724121","Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Currently receiving or planning to receive a BTKi or venetoclax.\n2. Male or female, aged 18 or older\n3. Stated willingness to comply with all study procedures and availability for the duration of the study\n4. Ability of subject to understand and the willingness to sign a written informed consent document\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Any acute cardiac condition including myocardial infarction or decompensated heart failure within the past 3 months\n2. Pregnancy or lactation- use of BTK inhibitors is contraindicated in pregnant or nursing individuals.","110 Years",{"count":116,"type":22},135,"Background:\n\nBruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart.\n\nObjective:\n\nTo identify and monitor the effects of BTKi on the heart.\n\nEligibility:\n\nPeople aged 18 and older currently receiving or planning to receive BTKi or venetoclax.\n\nDesign:\n\nParticipants who have not yet started BTKi will have 2 required clinic visits: 1 before they start taking BTKi, and 1 about 6 months later. Participants who are already taking BTKi will have 1 required visit.\n\nParticipants will undergo multiple tests:\n\nA physical exam, including collection of blood and saliva.\n\nA test that measures heart activity via stickers placed on the chest.\n\nA test that uses sound waves to capture images of the heart.\n\nAn exercise stress test that monitors heart activity and blood pressure while the participant works on a treadmill or stationary bike. Sound wave images of the heart may also be taken while the participant exercises.\n\nStress magnetic resonance imaging (MRI) may be done in place of an exercise test. Participants will lie on a table that slides into a tube. They will be given drugs to stress the heart while images are taken.\n\nParticipants may wear a device to monitor their heart at home.\n\nParticipants may have repeat visits if they develop heart symptoms or if they need to stop taking BTKi. They will have follow-up phone calls each year for up to 3 years.",[26,119,120,121,122,123],"Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia","Mantle Cell Lymphoma","Sudden Cardiac Death","Cardiac Arrhythmias","Hematologic Malignancies",[125,26,126,127,128,129],"SUDDEN CARDIAC DEATH","Ibrutinib Treatment","Atrial Fibrillation\u002FFlutter","Ventricular Arrhythmias","Natural History",{"date":100,"type":40},{"date":132,"type":40},"2023-03-01",{"date":134,"type":22},"2027-04-08",{"name":136,"class":137},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":88,"phases":147,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100609970","phase-2-a-study-of-nx-5948-in-adults-with-cllsll-previously-treated-with-a-brutons-tyrosine-kinase-inhibitor-and-a-b-cell-lymphoma-2-inhibitor-daybreak-cll-201-100609970","NCT07221500","A Study of NX-5948 in Adults With CLL\u002FSLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed\u002FRefractory (R\u002FR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* Confirmed relapsed\u002Frefractory CLL\u002FSLL that meets iwCLL criteria for diagnosis and systemic treatment\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Must have received a covalent BTK inhibitor (BTKi), a non-covalent BTKi, and a BCL-2 inhibitor either in separate lines of therapy or in combination; a line of therapy is considered 2 or more consecutive cycles of a systemic anti-CLL\u002FSLL regimen\n* Participants with SLL must have measurable disease by radiographic assessment\n* Adequate organ and bone marrow function\n* Must sign an informed consent form indicating that he or she understands the purpose of the procedures required for the study and is willing to participate\n\nExclusion Criteria:\n\n* Known or suspected prolymphocytic leukemia or Richter's transformation before entering study\n* Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) before planned start of study drug\n\n  * Antibody therapy must stop at least 4 weeks before the first dose of study drug\n  * No other systemic anticancer therapy is allowed at the same time as this study; exception: continuation of hormonal therapy for breast and prostate cancer is allowed, if they are not on the list of prohibited concomitant medications in this study\n* Palliative limited-field radiotherapy within 7 days of the first dose of study or broad field radiotherapy within 28 days of first dose of study drug\n* Use of systemic corticosteroids \\>20 mg\u002Fday prednisone or equivalent within the 7 days before start of study drug except for those used as premedication for radio diagnostic contrast\n* Use of systemic immunosuppressive drugs other than systemic corticosteroids within 60 days before the first dose of study drug\n* Previously treated with a BTK degrader\n* Previous chimeric antigen receptor (CAR) T-cell therapy or allogeneic or autologous hematopoietic cell transplant within the past 90 days prior to enrollment\n* Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage within 6 months of planned start of study drug\n\nNote: Other Inclusion\u002FExclusion criteria may apply as defined in the protocol.",{"count":146,"type":22},100,[90],"This is a study for patients with relapsed\u002Frefractory (R\u002FR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL\u002FSLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.",[26,93],[151,152,153,154,155,156,157,158,159,26,93],"BTK Degrader","BTK Inhibitor","BCL-2 Inhibitor","B-cell Malignancy","Lymphoma","Bruton's Tyrosine Kinase","NX-5948","Targeted Protein Degradation","Chimeric Targeting Molecule (CTM)","2026-06-30",{"date":100,"type":40},{"date":163,"type":40},"2025-10-15",{"date":165,"type":22},"2030-10",{"name":167,"class":47},"Nurix Therapeutics, Inc.",32,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":88,"phases":178,"briefSummary":180,"conditions":181,"keywords":186,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},"100449326","phase-1-a-study-of-nx-5948-in-adults-with-relapsedrefractory-b-cell-malignancies-100449326","NCT05131022","A Study of NX-5948 in Adults With Relapsed\u002FRefractory B-cell Malignancies","A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed\u002FRefractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years\n* Patients in Phase 1a (Dose Escalation) must have histologically confirmed R\u002FR CLL, SLL, DLBCL (subgroups include Richter-transformed DLBCL, germinal center B-cell type, activated B-cell type, high-grade B-cell lymphoma with MYC and BCL-2 and\u002For BCL-6 rearrangements, high-grade B-cell lymphomas NOS), FL, MCL, MZL (subtypes include EMZL, MALT, NMZL, SMZL), WM, or PCNSL.\n* Patients in Phase 1a must meet the following:\n\n  o For non-PCNSL indications, received at least 2 prior lines of therapy and have no other available therapies known to provide clinical benefit. For PCNSL, received at least 1 prior line of therapy\n* Patients in Phase 1b (Safety and Cohort Expansion) must have 1 of the following histologically documented B-cell malignancies, must meet criteria for systemic treatment, and must have received prior therapies and\u002For molecular features based on details described for each cohort: CLL or SLL, DLBCL, MCL, FL, MZL, WM, or PCNSL\u002FSCNSL.\n* Measurable disease per response criteria specific to the malignancy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (0-2 for patients with PCNSL and secondary CNS involvement).\n* Adequate organ and bone marrow function\n\nKey Exclusion Criteria:\n\n* Known or suspected active prolymphocytic leukemia or Richter's transformation to Hodgkin's lymphoma prior to study enrollment\n* Prior treatment for the indication under study for anti-cancer intent that includes:\n\n  1. Radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation).\n  2. Prior systemic chemotherapy within 2 weeks of planned start of study drug.\n  3. Prior monoclonal antibody therapy within 4 weeks of planned start of study drug, except for patients enrolling in Cohort 16 (CLL with secondary wAIHA) where a 16-week washout period is required.\n  4. Prior small molecule therapy within 2 weeks or 5 half-lives (whichever is shorter) of planned start of study drug.\n  5. Autologous or allogeneic stem cell transplant within 100 days prior to planned start of study drug.\n  6. Chimeric antigen receptor (CAR) T-cell therapy within 100 days prior to start of study drug (within 60 days prior to start of study drug for Phase 1b).\n  7. Use of systemic corticosteroids outside of dosing limits described below and within 7 days prior to initiation of study treatment excepting those used as prophylaxis for radio diagnostic contrast. Patients with PCNSL\u002FSCNSL: no greater than 40 mg\u002Fday prednisone, or equivalent. Patients with PCNSL\u002FSCNSL using greater than 20 mg\u002Fday prednisone, or equivalent, must be clinically stable at that dose for 7 days. All other diagnoses: no greater than 20 mg\u002Fday prednisone or equivalent.\n  8. Use of systemic immunosuppressive drugs other than systemic corticosteroids for any medical condition within 60 days prior to first dose of study drug\n  9. Previously treated with a BTK degrader\n* Active, uncontrolled autoimmune hemolytic anemia (except for patients enrolling in Cohort 16) or active, uncontrolled autoimmune thrombocytopenia.\n* Patient has any of the following within 6 months of planned start of study drug:\n\n  1. Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, or placement of a coronary arterial stent\n  2. Uncontrolled atrial fibrillation or other clinically significant arrhythmias, conduction abnormalities, or New York Heart Association (NYHA) class III or IV heart failure\n  3. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage\n  4. Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, severe congenital heart disease, or persistent uncontrolled hypertension defined as systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg despite optimal medical management)\n* Bleeding diathesis, or other known risk for acute blood loss.\n* History of Grade ≥ 2 hemorrhage within 28 days of planned start of study drug.\n* Active known concurrent malignancy or malignancy other than the one under study within the past 3 years. (Exceptions include, but are not limited to, patients with more recent history of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast may enroll if they have undergone curative therapy and have no evidence of disease).",{"count":177,"type":22},572,[179],"PHASE1","This is a first-in-human Phase 1a\u002F1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.",[26,93,182,63,64,65,183,184,185],"Diffuse Large B Cell Lymphoma (DLBCL)","Waldenstrom Macroglobulinemia (WM)","Primary Central Nervous System Lymphoma (PCNSL)","Secondary Central Nervous System Lymphoma (SCNSL)",[151,152,187,155,188,189,156,157,158,159],"B-Cell Malignancy","C481","C481S",{"date":100,"type":40},{"date":192,"type":40},"2022-04-13",{"date":194,"type":22},"2028-01",{"name":167,"class":47},62,{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":88,"phases":206,"briefSummary":208,"conditions":209,"keywords":214,"overallStatus":223,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100641819","connected-blood-pressure-monitoring-in-patients-with-hematologic-malignancies-initiating-covalent-btk-inhibitors-100641819","NCT07592481","Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors","HEMO-CONNECT","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of lymphoid malignancy: chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, or mantle cell lymphoma\n* Initiation of oral BTK inhibitor therapy (ibrutinib, acalabrutinib, or zanubrutinib), in treatment-naive or relapsed patients\n* Affiliation with a social security system\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Known cognitive impairment\n* No internet access\n* Individuals under guardianship, curatorship, or legal protection",{"count":205,"type":22},40,[207],"NA","This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase inhibitors (cBTKi). The objective is to determine whether digital BP monitoring improves early detection and management of BTKi-induced hypertension over 6 months.",[26,210,211,212,213,120],"Follicular Lymphoma ( FL)","Waldenstrom Macroglobulinaemia","Lymphoplasmacytic Lymphoma","Marginal Zone B Cell Lymphoma",[215,216,217,218,219,220,221,222],"BTK inhibitor","Hypertension","Telemonitoring","Connected device","Blood pressure","Lymphoid malignancies","Advanced practice nursing","Cardio-oncology","NOT_YET_RECRUITING","2026-06-18",{"date":226,"type":40},"2026-06-22",{"date":98,"type":22},{"date":229,"type":22},"2027-12-31",{"name":231,"class":232},"Centre Hospitalier de la côte Basque","OTHER",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":240,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":76},"100643081","impact-of-targeted-therapy-on-cancer-related-cognitive-impairment-100643081","NCT07638007","Impact of Targeted Therapy on Cancer-Related Cognitive Impairment","TKI","Inclusion Criteria:\n\n* TKI RECIPIENTS: Participants must have a diagnosis of CML or CLL\n* TKI RECIPIENTS: Participants must be scheduled to receive their first dose of TKI therapy for CML or CLL within 30 days or have received their first dose of TKI therapy for CML or CLL within the previous 30 days\n* TKI RECIPIENTS: Participants must be ≥ 18 years of age\n* TKI RECIPIENTS: Participants must be able to speak and read English\n* TKI RECIPIENTS: Participants must be able to understand and willing to sign an informed consent document\n* CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be ≥ 18 years of age\n* CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be able to speak and read English\n* CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be able to understand and willing to sign an informed consent document\n* CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Each participant must be matched to a TKI recipient participant based on sex and age ±5 years (i.e., must be no more than 5 years older or younger than the TKI recipient participant)\n\nExclusion Criteria:\n\n* Participants must have no history of metastatic cancer, primary brain tumor, or brain irradiation\n* Participants must have no history of TKI therapy\n* Participants must have no history of cytotoxic chemotherapy, immune checkpoint inhibitor therapy, hormonal therapy, biologic therapy, radiotherapy within the past 5 years. However, permitted treatments include prior use of hydroxyurea for the treatment of CML or CLL as well as treatment with obinutuzumab or rituximab concurrent with TKI therapy for CLL\n* Participants must have no history of stroke within the past year and no remaining cognitive symptoms from any stroke prior to the past year\n* Participants must have no history of head trauma with loss of consciousness within the year prior to consent\n* Participants must have no diagnosis of dementia or severe neurodegenerative disease impairing daily functioning\n* Participants must have no psychiatric condition that led to hospitalization within the past year\n* Participants must not be currently pregnant\n* Participants must not be colorblind based on self-report\n* Participants must not be study staff who have previously viewed or administered the objective cognitive function measures (e.g., CANTAB)",true,{"count":242,"type":22},400,"This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.",[245,26,246],"Disease\u002FCondition Name Cancer-related Cognitive Dysfunction","Chronic Myeloid Leukemia, BCR-ABL1 Positive","2026-06-05",{"date":249,"type":40},"2026-06-10",{"date":251,"type":40},"2025-11-21",{"date":253,"type":22},"2029-02-28",{"name":255,"class":232},"University of Rochester NCORP Research Base",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":240,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":265,"conditions":266,"keywords":271,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":4,"leadSponsor":280,"locationsCount":76},"100139553","collection-of-human-samples-to-study-hairy-cell-and-other-leukemias-and-to-develop-recombinant-immunotoxins-for-cancer-treatment-100139553","NCT01087333","Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment","A Study of Hairy Cell and Other Leukemias With a Focus on Recombinant Immunotoxins for Cancer Treatment","* INCLUSION CRITERIA:\n\nAll participants\n\n* 18 years of age and older\n* Desire of the individual to submit data and samples for research\n* Ability to understand and the willingness to sign a written informed consent document.\n\nIndividuals with cancer\n\n-Participants may have a diagnosis of hematologic malignancy or solid tumor. These participants would not be excluded if they were in long-term complete remission.\n\nNormal donors (Individuals without cancer)\n\n-Individuals must not have a current or prior diagnosis of a hematologic malignancy or solid tumor.\n\nEXCLUSION CRITERIA:\n\nAll participants\n\n-Known pregnancy at enrollment. NOTE: A pregnancy test will be required in individuals on study prior to any procedure done for research purposes that is greater than minimal risk.",{"count":264,"type":22},1263,"Background:\n\n\\- Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers. The investigators are particularly interested in samples from individuals who have diseases that can be treated with a new type of drug called immunotoxin, in which an antibody carrying a toxin binds to a cancer cell and allows the toxin to kill the cell.\n\nObjectives:\n\n\\- To collect a variety of clinical samples, including blood, urine, lymph samples, and other tissues, in order to study the samples and develop new treatments for leukemia.\n\nEligibility:\n\n\\- Individuals 18 years of age and older who have been diagnosed with leukemia or other kinds of blood and lymphatic system cancers, or who are healthy volunteers.\n\nDesign:\n\n* Individuals who have leukemia will be asked to provide blood, bone marrow, urine, and tumor tissue samples as requested by the researchers. Healthy volunteers will provide only blood and urine samples.\n* No treatment will be given as part of this protocol.",[267,26,268,269,270],"Hairy Cell Leukemia (HCL)","Non-Hodgkins Lymphoma (NHL)","Cutaneous T Cell Lymphoma (CTCL)","Adult T Cell Lymphoma (ATL)",[272,273,274,275,276,129],"Cytotoxicity Assay","Neutralizing Antibodies","Apheresis","Flow Cytometry","Hemolytic Uremic Syndrome (HUS)",{"date":247,"type":40},{"date":279,"type":40},"2010-03-02",{"name":281,"class":137},"National Cancer Institute (NCI)",{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":88,"phases":290,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":76},"100625905","early-phase-1-immune-profiling-of-cllsll-treated-with-first-line-pirtobrutinib-100625905","NCT07428707","Immune Profiling of CLL\u002FSLL Treated With First-Line Pirtobrutinib","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures\n2. Age \\>=18 years\n3. Confirmed diagnosis of CLL or SLL according to International Workshop on CLL (iwCLL) guidelines\n\n   1. Coexpression of CD5, CD19, CD20, and CD23 expression and light-chain restriction; CD23 dim or negative expression is acceptable as long as other parameters are consistent with a diagnosis of CLL.\n   2. CLL: clonal B-lymphocytosis \\>=5,000 cells\u002FmL\n\n   OR\n\n   SLL: lymphadenopathy with the tissue morphology of CLL but that are not leukemic, \\\u003C5,000 cells\u002FmL\n4. Active disease requiring treatment according to iwCLL guidelines\n5. Measurable disease characterized by \\>=1 of the following:\n\n   1. Lymphadenopathy: \\>=1 lymph node measuring \\>=1.5 cm in the greatest diameter\n   2. Splenomegaly: spleen measuring \\>13 cm in craniocaudal length\n   3. Lymphocytosis: \\>=5,000 B cells\u002FmicroL\n   4. Bone marrow infiltration: CLL comprising \\>= 30% of all cells\n6. Previously untreated CLL with \\>=1 LN amenable to core-needle biopsy\n7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n8. The patient has adequate organ function for all of the following criteria, as defined below:\n\n   * System: Hepatic\n\n     * Laboratory Value: ALT or AST: \\\u003C= 3 x the ULN or \\\u003C= 5 x ULN with documented liver involvement\n     * Laboratory Value: Total bilirubin: \\\u003C= 1.5 x ULN or \\\u003C= 3 x ULN with documented liver involvement and\u002For Gilbert s Disease\n   * System: Renal\n\n     --Laboratory Value: Serum creatinine: Calculated creatinine clearance \\>= 30 ml\u002Fmin according to Cockcroft\u002FGault Formula: \\[(140-age) x body weight (kg) x 0.85 (if female)\\]\u002F \\[serum creatinine (mg\u002FdL) x 72\\]\n   * System: Hematologic\n\n     * Laboratory Value: Hemoglobin: \\>= 8 g\u002FdL (\\>= 80 g\u002FL)\n     * Laboratory Value: ANC: \\>= 0.75 x 10\\^9\u002FL\n     * Laboratory Value: Platelets: \\>= 50 x 10\\^9\u002FL\n\n   Notes:\n\n   Hgb and platelets: independent of transfusions within 7 days of Screening assessment.\n\n   ANC: independent of growth factor support within 7 days of Screening assessment.\n\n   Criteria must be met on C1D1 without transfusion\u002FG-CSF within 7 days of assessment.\n\n   Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST =aspartate aminotransferase; ULN = upper limit of normal.\n9. Adequate coagulations, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or international normalized ratio (INR) not greater than 1.5 X ULN.\n10. Willingness of WOCBP and their partners to observe highly effective birth control methods for the duration of treatment and for 1 month following the last dose of study treatment.\n11. Ability to take oral medication and be willing to adhere to the study drug regimen\n12. Agreement to adhere to Lifestyle Considerations throughout study duration\n13. Able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n1. Diagnosis of Richter Transformation\n2. Documented CNS involvement\n3. Pregnancy or plan to become pregnant during the study or within 1 month of the last dose of study treatment. WOCBP must have a negative serum pregnancy test.\n4. Lactation or plan to breastfeed during the study or within 1 week of the last dose of study treatment.\n5. Known active cytomegalovirus (CMV) infections. Unknown or negative status are eligible.\n6. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below:\n\n   1. Patients with positive hepatitis B surface antigen (HBsAg) are excluded.\n   2. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require a negative hepatitis B polymerase chain reaction (PCR) evaluation before randomization.\n   3. Patients who are HBV DNA PCR positive will be excluded.\n7. Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be excluded.\n8. Patients who have tested positive for Human Immunodeficiency Virus (HIV) and have a detectable viral load and\u002For a CD4 count \\\u003C350 are excluded due to risk of opportunistic infections with both HIV and BTK inhibitors. Eligible patients with HIV must be stable on antiretroviral therapy \\>=4 weeks prior to study entry. For patients with unknown HIV status, HIV testing will be performed at Screening and result must be negative for enrollment.\n9. Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug. (e.g., gastric bypass surgery, gastrectomy).\n10. Evidence of other clinically significant uncontrolled condition(s) including but not limited to, uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and medical monitor may pose a risk for patient participation. Screening for chronic conditions is not required.\n11. Stroke or intracranial hemorrhage within 6 months of screening\n12. Hypertensive urgency or emergency\n13. Active, clinically significant cardiovascular disease including:\n\n    * Unstable angina or acute coronary syndrome within the past 2 months prior to screening\n    * Documentation of LVEF by any method of \\\u003C= 40% in the 12 months prior to screening\n    * Uncontrolled or symptomatic arrhythmias\n    * Class 3 or 4 congestive heart failure as defined by New York Heart Association Functional Classification\n    * Myocardial infarction, unstable angina or acute coronary syndrome within 3 months of screening.\n    * Prolongation of the QT interval corrected for heart rate (QTcF) \\> 470 msec. QTcF is calculated using Fridericia s Formula (QTcF): QTcF=QT\u002F(RR\\^0.33)\n\n    Correction of suspected drug-induced QTcF prolongation can be attempted at the investigator s discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.\n\n    \\- Correction for underlying bundle branch block (BBB) allowed.\n\n    Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker\n14. Known allergy\u002Fsensitivity to pirtobrutinib or any of the excipients (hydroxypropyl methylcellulose acetate succinate, microcrystalline cellulose, mannitol, sodium starch glycolate, and magnesium stearate.).\n15. History of bleeding diathesis (e.g. von Willebrand disease or hemophlia)\n16. Has received a live vaccine or live-attenuated vaccine within 28 days before the first dose of pirtobrutinib. Administration of killed vaccines are allowed.\n17. Patients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist are excluded. Direct oral anticoagulants (DOACs) are allowed.\n18. Diagnosis of primary immunodeficiency or is receiving chronic systemic steroid therapy (in dosing \\>20 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.\n19. Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid)\n20. Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia \\[AIHA\\], idiopathic thrombocytopenic purpura \\[ITP\\]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.\n21. Active second malignancy unless in remission and with life expectancy \\>2 years.\n\n    Note: Participants are eligible if they have prostate cancer under active surveillance or observation.\n22. Has not adequately recovered after 4 weeks from major surgery or has ongoing surgical complications.\n23. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n24. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant s participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.","100 Years",{"count":5,"type":22},[291],"EARLY_PHASE1","Background:\n\nChronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. Pirtobrutinib is a drug approved to treat CLL and SLL after 2 previous treatments. Researchers want to know how this drug affects the immune system in those who have not yet started other treatments for CLL or SLL.\n\nObjective:\n\nTo test pirtobrutinib as a first-line treatment for CLL or SLL.\n\nEligibility:\n\nPeople aged 18 years and older with untreated CLL or SLL.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood tests. They will have imaging scans and tests of their heart function. They will have a lymph node biopsy: A large needle will be inserted into a lymph node to collect a small piece of tissue.\n\nPirtobrutinib is a tablet taken by mouth. Participants will take 2 to 4 tablets daily in 4-week cycles.\n\nParticipants will have clinic visits once every 4 weeks for the first 3 months. Then they will be seen once every 3 months.\n\nImaging scans, lymph node biopsy, and other tests will be repeated at various study visits.\n\nA bone marrow biopsy (collection of soft tissue from inside a bone) may be done if there is no evidence of disease after 1 year of treatment with the study drug.\n\nParticipants may opt to have cancer and immune cells collected from their blood. The cells will be used for research.\n\nParticipants will have a clinic visit 1 month after their last dose of the study drug. Then they will have follow-up visits or phone calls every 6 to 12 months....",[26,93],[295,26,296],"Pirtobrutinib","Immune profiling","2026-06-03",{"date":102,"type":40},{"date":300,"type":40},"2026-03-11",{"date":302,"type":22},"2030-03-01",{"name":136,"class":137},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":312,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":327},"100482105","observational-study-of-acalabrutinib-in-patients-with-chronic-lymphocytic-leukaemia-in-the-united-kingdom-100482105","NCT05557695","Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom","A Non-interventional, Observational Cohort Study of Chronic Lymphocytic Leukaemia Patients Treated With Acalabrutinib in the First-line Setting Through the UK Early Access Programme: Early Access Programme Outcomes In aCalabrutinib (EPIC).","EPIC","The study population will include treatment-naïve patients with chronic lymphocytic lymphoma (CLL)\\* who meet the following inclusion criteria:\n\n* Treatment-naïve CLL patients who were initiated on acalabrutinib as part of the UK Early Access Programme\n* Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021\n* Patients aged ≥18 years old\n\n  * Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP.\n\nExclusion Criteria:\n\n\\- None listed in study protocol",{"count":313,"type":22},350,"This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.",[316],"Chronic Lymphocytic Leukemia, CLL",[318],"CLL, real-world evidence, acalabrutinib","2026-06-01",{"date":321,"type":40},"2026-06-02",{"date":323,"type":40},"2022-10-17",{"date":325,"type":22},"2027-04-01",{"name":106,"class":47},29,{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":88,"phases":337,"briefSummary":338,"conditions":339,"keywords":343,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":356},"100556684","phase-1-a-phase-1-study-of-ub-vv111-with-and-without-rapamycin-in-relapsedrefractory-cd19-b-cell-malignancies-100556684","NCT06528301","A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed\u002FRefractory CD19+ B-cell Malignancies","A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed\u002FRefractory (R\u002FR) CD19+ B-cell Malignancies","Inclusion Criteria:\n\n1. 18 years or older\n2. Provides voluntary written informed consent\n3. Relapsed or refractory large B-cell lymphoma (LBCL) or chronic lymphocytic leukemia (CLL)\n4. Measurable disease according to Lugano 2014 criteria (LBCL) or iwCLL 2018 (CLL).\n5. No serious concomitant diseases or active\u002Funcontrolled infections\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Adequate organ function\n8. Patients who have previously received CD19-directed therapy must have biopsy confirming CD19 expression following completion of prior CD19-directed therapy.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding\n2. Current isolated central nervous system (CNS) involvement\n3. Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (exceptions include tumor-infiltrating lymphocytes and CAR T cells)\n4. History of or active human immunodeficiency virus (HIV)\n5. Active hepatitis B or C\n6. Systemic immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease\n7. Ongoing CNS disease that would preclude neurologic assessment\n8. Uncontrolled angina or other acute heart disease\n9. Currently receiving treatment in another interventional clinical trial.",{"count":336,"type":22},106,[179],"This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed\u002Frefractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).",[340,341,342,26],"Lymphoma, B-Cell","Lymphoma, Non-Hodgkin (NHL)","Lymphoma, Large B-Cell, Diffuse (DLBCL)",[344,345,346],"CAR T","CD19","chimeric antigen receptor","2026-05-26",{"date":349,"type":40},"2026-05-28",{"date":351,"type":40},"2025-03-10",{"date":353,"type":22},"2029-03",{"name":355,"class":47},"Umoja Biopharma",8,{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":88,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":381},"100608727","early-phase-1-a-clinical-study-evaluating-the-safety-and-efficacy-of-gt801-injection-in-adult-patients-with-relapsedrefractory-cd19-positive-b-cell-hematologic-malignancies-and-autoimmune-hemolytic-anemia-100608727","NCT07205315","A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed\u002FRefractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia","Inclusion Criteria:\n\n* Aged 18 to 75 years (inclusive), male or female;\n* Participants with refractory or relapsed acute B-cell lymphoblastic leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL) confirmed by the WHO 2016 Classification, or Autoimmune Hemolytic Anemia (AIHA) diagnosed in accordance with international consensus;\n* Disease progression or recurrence after at least second-line drug treatment;\n* CD19 positivity confirmed by flow cytometry and\u002For histopathology (excluding autoimmune hemolytic anemia);\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1(excluding autoimmune hemolytic anemia);\n* Expected survival period \\> 12 weeks\n* For participants with hematological malignancies, the following requirements must be met:\n\nFor any prior systemic therapy (excluding immune checkpoint inhibitors), an interval of at least 2 weeks or 5 half-lives (whichever is shorter) must have elapsed between the last dose of such therapy and the planned initiation of study treatment.\n\nFor any prior treatment with immune checkpoint inhibitors (e.g., anti-PD-1\u002FPD-L1 monoclonal antibodies such as pembrolizumab, OX40 agonists, 4-1BB agonists, etc.), an interval of at least 3 half-lives or 28 days (whichever is shorter) must have elapsed between the last dose of such treatment and the planned initiation of study treatment.\n\n• For participants with autoimmune hemolytic anemia (AIHA), the following requirements must be met: The total course of glucocorticoid therapy shall be no less than 3 months (except for those who are unable to tolerate due to severe infection, fracture, etc.); Rituximab (100 mg or 375 mg\u002Fm²) shall be administered for at least 4 times, with hemoglobin (HB) remaining below 100 g\u002FL at 12 weeks after the first dose; or rituximab (1000 mg per administration) shall be administered for at least 2 times, with hemoglobin (HB) remaining below 100 g\u002FL at 12 weeks after the first dose; oral administration of any one of the following drugs including mycophenolate mofetil, cyclosporine, azathioprine, cyclophosphamide, etc., shall last for at least 4 months or be discontinued due to intolerance; or intravenous therapy with fludarabine or cyclophosphamide injection shall be administered for at least 2 cycles; or subcutaneous injection of bortezomib shall be administered for at least 4 times.\n\nExclusion Criteria:\n\n* Participants with a history of central nervous system leukemia\u002Flymphoma, or those with central nervous system (CNS) leukemia\u002Flymphoma shown by magnetic resonance imaging (MRI) or PET-CT intracranial imaging during the screening period, or those with detectable malignant cells in cerebrospinal fluid or brain metastases;\n* Subjects with myelofibrosis, myelodysplastic syndromes, aplastic anemia, or other malignant hematological diseases;\n* Subjects with a history of or current comorbidities that cause coagulation disorders and high bleeding risk, such as disseminated intravascular coagulation (DIC), decompensated cirrhosis, esophagogastric varices, etc.;\n* Subjects who experienced severe bleeding (defined as bleeding uncontrollable by medication or local therapy) within 4 weeks prior to screening, or have life-threatening bleeding (associated with thrombocytopenia) currently, or are expected to require emergency treatment within one week after enrollment;\n* Subjects with secondary AIHA induced by drugs or infections;\n* Subjects with hereditary hemolytic diseases or other acquired hemolytic diseases.\n* Participants who undergo hematopoietic stem cell transplantation with therapeutic intent within 12 weeks of planned GT801 infusion;\n* If the participant has a history of hematopoietic stem cell transplantation, the time since the participant received allogeneic hematopoietic stem cell transplantation is ≤ 6 months;\n* Administration of hormonal drugs in any form within 14 days prior to infusion (except for AIHA participants requiring such drugs for hemolysis control and those receiving them for preconditioning).\n* Active hepatitis B and\u002For active hepatitis C (HCV RNA positive); participants who are positive for hepatitis B surface antigen and\u002For core antibody but have HBV-DNA test results within the normal range can be included; participants who are positive for hepatitis C virus (HCV) antibody but with HCV RNA test results within the normal range are eligible for inclusion.\n* Presence of central nervous system diseases or a history thereof, such as epileptic seizures, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar diseases, or any autoimmune diseases involving the central nervous system;\n* Presence of any of the following conditions within 6 months before signing the informed consent form: uncontrolled congestive heart failure (New York Heart Association Class III-IV), angina pectoris, myocardial infarction, cardiomyopathy, stroke (except lacunar infarction), coronary\u002Fperipheral artery bypass surgery, arrhythmias with significant clinical significance (as judged by the investigator) including but not limited to ventricular arrhythmias, significantly prolonged QT interval (recommended QTc ≥ 500ms corrected by Bazett's method, specifically judged by the investigator), poorly controlled hypertension (systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg), poorly controlled diabetes, pulmonary embolism, diffuse pulmonary lesions, pulmonary insufficiency, or medical conditions that the investigator deems unsuitable for the participant to participate in this clinical study;\n* Prior receipt of gene-modified or gene-edited cellular therapy products (except for autologous immune cell therapy products without gene modification or editing, provided that the interval from the last administration to the first dose of GT801 is more than 1 year).\n* A history of autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus) that caused end-organ damage or required systemic immunosuppression\u002Fsystemic disease-modifying agents within the past 2 years.","75 Years",{"count":365,"type":22},28,[291],"The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed\u002Frefractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia. Interim analysis conducted when 2 patients complete primary endpoint measurement.",[369,26,370,371],"B-cell Acute Lymphoblastic Leukemia (B-ALL)","B-cell Non-Hodgkin's Lymphoma (B-NHL)","Autoimmune Hemolytic Anemia (AIHA)","2026-05-22",{"date":374,"type":40},"2026-05-27",{"date":376,"type":40},"2025-09-26",{"date":378,"type":22},"2028-08-31",{"name":380,"class":47},"Grit Biotechnology",2,{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":88,"phases":391,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":356},"100349029","phase-2-study-of-zanubrutinib-obinutuzumab-and-venetoclax-in-patients-with-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-leukemia-sll-100349029","NCT03824483","Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)","Phase 2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)","Inclusion Criteria:\n\n\\- Signed, informed consent\n\n* Ability and willingness to comply with the requirements of the study protocol\n* Age ≥18 years\n* Diagnosis of the following histories according to the WHO criteria\n\n  1. CLL or SLL\n  2. MCL\n* For patients with SLL, peripheral blood flow cytometry must be positive with CLL-like cells accounting for at least 1% of circulating WBC.\n* No prior systemic therapy for disease under study except:\n\n  1. prior local radiation for symptomatic disease is permitted\n  2. Short course systemic corticosteroids is permissible for disease control, improvement of performance status or non-cancer indication (must be ≤ 14 days and \\\u003C 100 mg\u002Fday prednisone or ≤ 20 mg\u002Fday dexamethasone). Steroids must be discontinued prior to study treatment. Inhaled steroids for asthma, topical steroids, and replacement\u002FStress corticosteroids are permitted. Low-dose steroids for ITP are also permitted up to the equivalent prednisone 20mg\u002Fdaily at time of eligibility review.\n* ECOG performance status of 0 to 2\n* Adequate hematologic parameters unless due to disease under study:\n\n  1. Absolute neutrophil count (ANC) ≥1.0 x 109\u002FL unless neutropenia is clearly due to disease under study (per investigator discretion)\n  2. Platelet count ≥ 75,000\u002Fmm3 - OR - Platelet count ≥ 20,000\u002Fmm3 if thrombocytopenia is clearly due to disease under study (per investigator discretion)\n  3. Hemoglobin ≥9.0 g\u002FdL unless anemia is clearly due to marrow involvement due to disease under study (per investigator discretion)\n* Adequate renal and hepatic function, per laboratory reference range at Screening as follows:\n\n  a. AST\u002FSGOT, ALT\u002FSGPT ≤2.0 x ULN b. Total bilirubin ≤ 2.0 x ULN unless:\n\n  i. Considered secondary to Gilbert\"s syndrome, in which case ≤3 x ULN ii. Considered due to disease under study (Per PI or Co-PI discretion)\n\n  c. Creatinine clearance of eGFR\\>30 mL\u002Fmin according to the Cockcroft-Gault Equation\n* For females of childbearing potential, a negative serum pregnancy test within 7 days of study treatment\n* For female patients of childbearing potential, agreement to use highly effective form(s) of contraception (i.e., one that results in a low failure rate \\[\\\u003C1% per year\\] when used consistently and correctly) or remain abstinent (refrain from heterosexual intercourse) during the treatment period and to continue its use for 90 days after the last dose of zanubrutinib AND 30 days after the last dose of venetoclax AND for 18 months after the last dose of obinutuzumab (whichever date is later)\n\nA woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (\\>\u002F= 12 continuous months of amenorrhea with no identified cause other than menopause), and it not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and\u002For uterus) or another cause as determined by the investigator (e.g., Mullerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations.\n\nExamples of contraceptive methods with a failure rate of \\\u003C1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Hormonal contraceptive methods must be supplemented by a barrier method.\n\n1. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n\n   * For men with a female partner of childbearing potential or a pregnant female partnet: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom during the treatment period and to continue its use for 90 days after the last dose of zanubrutinib AND, 30 days after the last dose of venetoclax AND for 18 months after the last dose of obinutuzumab (whichever date is later)\n\n   The reliability of sexual abstinence should be evaluated in relation duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception - Willingness to not donate or bank sperm or oocytes during the entire study treatment period and after treatment discontinuation for 90 days after the last dose of zanubrutinib AND 30 days after the last dose of venetoclax AND for 18 months after the last dose of obinutuzumab (whichever date is later)\n\n   Additional Eligibility Criteria for CLL Cohort:\n\n   1\\. Diagnosis of untreated CLL or SLL according to WHO criteria 2. For patients with SLL, peripheral blood flow cytometry must be positive with CLL-like cells accounting for at least 1% of circulating WBC 3. No prior systemic therapy for CLL: prior single site of local radiation for symptomatic disease is permitted 4. Subject requires treatment according to IWCLL guidelines (See Appendix A)\n\n   Additional Eligibility Criteria for TP53 Mutant MCL cohorts:\n\n   1\\. Diagnosis of untreated stage II-IV mantle cell lymphoma\n\na. Prior radiotherapy for localized disease is permitted 2. Presence of TP53 mutation irrespective of variant allele frequency (TP53 cohort)\n\nOR\n\nPresence of p53 overexpression by immunohistochemistry defined as strong nuclear staining of \\>30% positive nuclei.\n\nAdditional Eligibility Criteria for Transplant Ineligible MCL cohort:\n\n1. Diagnosis of untreated stage II-IV mantle cell lymphoma\n\n   1. Prior radiotherapy for localized disease is permitted\n2. Patients must meet one of the following criteria (a or b):\n\n   a. Age ≥65 years If age \\\u003C65 years of age, then patients must be ineligible for HDT\u002FASCT on the basis of comorbidity or organ dysfunction.\n\n   Specifically, patients must meet at least one of the following criteria below:\n\n   i.. Comorbid disease, such as CAD, CHF, pulmonary dysfunction, liver or kidney dysfunction, precluding high dose therapy secondary to expected increased morbidity and mortality. ii. ECOG 2 iii. Ejection fraction ≥35% and \\\u003C45% iv. Impaired pulmonary function test with DLCO \\\u003C50% expected v. Medical conditions which in the opinion of the treating physician in consultation with the study PI or Co-PI and DMT preclude HDT\u002FASCT.\n\n   Exclusion Criteria:\n\n   Other malignancies:\n   * Known active histological transformation from CLL to an aggressive lymphoma (i.e., Richter\"s transformation)\n   * Active malignancy or systemic therapy for another malignancy within 3 years; local\u002Fregional therapy with curative intent such as surgical resection or localized radiation within 3 years of treatment is permitted\n   * Other diagnosis of active cancer\n\n   Co-morbidities:\n\n   \\- Any uncontrolled illness that in the opinion of the investigator would preclude administration of study therapy (e.g. significant active infections, hypertension, angina, arrhythmias, pulmonary disease, or autoimmune dysfunction)\n   * Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1\n   * Known bleeding diathesis\n   * Prior major surgical procedure within 4 weeks of study, or anticipation of need for a major surgical procedure during the course of the study\n   * Known CNS hemorrhage or stroke within 6 months of the study\n   * History of progressive multifocal leukoencephalopathy (PML)\n   * History of HIV infection\n\n     1. Patients with a history of HIV infection that is well controlled on antiretroviral therapy are eligible if all of the following criteria are met: (1) undetectable HIV viral load by standard clinical assay AND (2) CD4+ T cell count of ≥ 200 cells\u002Fmicroliter\n\n   NOTE: Many HIV regimens are excluded based on drug interactions, and concomitant antiretroviral therapy need to cleared by the clinical pharmacist and approved by the site PI)\n   * Active hepatitis B (chronic or acute) or hepatitis C infection a. Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody \\[HBcAb\\] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to take appropriate anti-viral prophylaxis as indicated and undergo monthly DNA testing.\n\n     b. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA\n   * Congestive heart failure, New York Heart Association classification III\u002FIV\n   * Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis\n   * Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment\n   * Known condition or other clinical situation that would affect oral absorption\n   * Psychiatric illness\u002Fsocial situations that would interfere with study compliance\n   * Inability to swallow a large number of tablets\n\n   Concomitant medications and drug interactions:\n\n   \\- Administration within 7 days prior to the first dose of study drug or concurrent therapy with strong inhibitors or inducers of CYP3A, CYP2C8, CYP2C9 and CYP2C19. The same applied for moderate inhibitors or inducers of CY\\_3A\n   * Live-virus vaccines given within 28 days prior to the initiation of study treatment\n   * Immunotherapy\n   * Hormone therapy (other than contraceptives, hormone replacement therapy, or megestrol acetate)\n   * Any therapies intended for the treatment of lymphoma\u002Fleukemia whether FDA approved or experimental (outside of this study)\n   * Radiation therapy intended to treat MCL or CLL\u002FSLL\n   * Warfarin or warfarin derivatives\n   * Consumption of one or more of the following within 3 days prior to the first dose of study drug:\n\n   Grapefruit or grapefruit products Seville oranges, including marmalade containing Seville oranges Star Fruit (carambola)\n\n   Prior therapy:\n   * Prior anti-CD20 monoclonal antibody therapy for non-malignant indication\n   * Obinutuzumab is contraindicated in patients with a known hypersensitivity (IgE-mediated) reaction to obinutuzumab or to any of its excipients\n   * Prior systemic therapy for CLL; prior single site of local radiation for symptomatic disease is permitted\n\n   Other:\n   * Females who are currently pregnant or breastfeeding\n   * Participation in a separate investigational therapeutic study unless authorized by the investigator",{"count":390,"type":22},230,[90],"The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and\u002For SLL.",[26,394],"Small Lymphocytic Leukemia (SLL)",[396,397,398,399],"Zanubrutinib","Obinutuzumab","Venetoclax","18-427","2026-05-06",{"date":402,"type":40},"2026-05-07",{"date":404,"type":40},"2019-02-22",{"date":406,"type":22},"2027-02",{"name":408,"class":232},"Memorial Sloan Kettering Cancer Center",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":76},"100595280","predictors-of-health-related-qol-in-adults-with-cll-or-small-lymphocytic-lymphoma-100595280","NCT07030400","Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma","Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Inclusion Criteria:\n\n* All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +\u002F- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.\n* Subjects must be able to read and speak English or Spanish at the 8th grade level.\n\nExclusion Criteria:\n\n* Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.",{"count":146,"type":22},"The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.",[93,26],"2026-03-31",{"date":421,"type":40},"2026-04-01",{"date":423,"type":40},"2025-07-17",{"date":425,"type":22},"2028-06",{"name":427,"class":232},"H. Lee Moffitt Cancer Center and Research Institute",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":240,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":88,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":223,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":76},"100632077","phase-2-a-phase-2-trial-of-the-bruton-tyrosine-kinase-degrader-bgb-16673-in-combination-with-bcl-2-inhibitor-sonrotoclax-for-patients-with-treatment-naive-chronic-lymphocytic-leukemia-cll-100632077","NCT07508995","A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)","Inclusion Criteria:\n\n1. Patients with a diagnosis of previously untreated CLL\u002FSLL meeting iwCLL 2018 indication for treatment (Note: patients who receive steroids and\u002For CD20 monoclonal antibody for cytoreduction in those patients presenting with significantly elevated WBC count or significant adenopathy\u002Forganomegaly and those who previously received steroids\u002FCD20 monoclonal antibody for immune cytopenias are eligible to enroll; Washout of 4 weeks applies for CD20 monoclonal antibody and dose of prednisone (or equivalent) should be less than 20mg\u002Fday by day 1 of study initiation)\n2. Age ≥ 18 years\n3. Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2\n4. Adequate hepatic function a. Total bilirubin ≤1.5 x upper limit of normal (ULN) or ≤3 x ULN for patients with Gilbert's disease or documented disease involvement of liver (In pts with elevated total bilirubin due to increased indirect bilirubin, pts with direct bilirubin ≤1.5 x ULN are eligible) b. ALT and AST ≤3.0 x ULN, or ≤5.0 x ULN if documented disease involvement of liver\n5. Adequate renal function\n\n   1. Adequate renal function defined by a value ≥50 mL\u002Fmin determined via estimated GFR calculated according to the CKD-EPI equation\n6. Adequate hematologic function\n\n   a. Platelet count ≥50 x109\u002FL and hemoglobin ≥8 g\u002FdL (≥80 g\u002FL). Platelet and hemoglobin requirements are independent of transfusions within 7 days of screening assessment and first dose of study drugs. b. Absolute neutrophil count ≥0.75 x 109\u002FL. Absolute neutrophil count is independent of growth factor support within 7 days of screening assessment and first dose of study drugs.\n7. Adequate coagulation function a. INR ≤1.5 x ULN and aPTT ≤1.5 x ULN\n8. Ability to swallow tablets and comply with outpatient treatment, laboratory monitoring, and required clinic visit for the duration of study participation\n9. Women of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (β-hCG) pregnancy test result within 24 hours prior to the first dose of study drugs.\n10. The effects of sorotoclax and BGB-16673 on the developing human fetus are unknown. For this reason these agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n\n    o Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n\n    o History of hysterectomy or bilateral salpingo-oophorectomy.\n    * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n    * History of bilateral tubal ligation or another surgical sterilization procedure.\n\n      * Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Contraception should used for the duration of the study and up to 30 days after completion of BGB-16673 and\u002For sonrotoclax administration.\n      * Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and up to 30 days after completion of BGB-16673 and\u002For sonnrotoclax administration.\n11. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Major surgery within 4 weeks prior to the first dose of study drugs\n2. Uncontrolled active systemic infection\n3. Known positive serology for human immunodeficiency virus (HIV)\n4. Active hepatitis B infection (defined as the presence of detectable HBV DNA, HBe antigen or HBs antigen). Patients with serologic evidence of prior vaccination (HBsAg negative, anti-HBs antibody positive, anti-HBc antibody negative) are eligible. Patients who are HBsAg negative\u002FHBsAb positive but HBcAb positive are eligible, provided HBV DNA is negative and they are willing to take appropriate anti-viral prophylaxis\n5. Active hepatitis C infection (defined as detectable hepatitis C RNA in plasma by PCR)\n6. Known active cytomegalovirus (CMV) infection. Unknown or negative status are eligible\n7. Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy with \\>20 mg daily of prednisone or equivalent\n8. Clinically significant, uncontrolled cardiovascular disease (≥3 NYHA heart failure, uncontrolled or symptomatic arrythmias), or myocardial infarction within 6 months prior to start of study drugs\n9. Uncontrolled hypertension defined as 2 consecutive systolic blood pressure ≥160 mmHg and \u002For diastolic blood pressure ≥100 mmHg within 3 months\n10. History of Mobitz II second degree or third-degree heart block without a permanent pacemaker in place\n11. Prolongation of the QT interval corrected for heart rate (QTcF) \\>480 msec. Note: Patients with QTcF \\>480 msec should have EKG repeated. If QTcF again is \\>480 msec, then the patient should be referred to cardiology for evaluation. Patient can be enrolled later if cleared by cardiology and repeat QTcF less than 480 msec. QTcF is calculated using Fridericia's Formula (QTcF): QTcF = QT\u002F(RR0.33)\n\n    1. Correction of suspected drug-induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.\n    2. Correction for underlying bundle branch block (BBB) allowed. Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker\n12. Pregnancy, lactation or plan to breastfeed during the study or within 6 months of the last dose of study treatment\n13. Concurrent use of warfarin or another vitamin K antagonist\n14. Receiving treatment with a strong CYP3A inhibitor or strong CYP3A inducer ≤14 days or 5 halflives, whichever is longer, before the first dose of study treatment(s) OR requiring long-term use of strong CYP3A inhibitors or inducers.\n15. Patient has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment 16. Active second malignancy unless in remission and with life expectancy \\> 2 years with exception of patients diagnosed with basal cell or squamous cell carcinoma of the skin or carcinoma \"in situ\" of the cervix or breast who are eligible even if diagnosed within 2 years. If patients have another malignancy that was treated within the last 2 years, such patients may be enrolled, if the likelihood of requiring systemic therapy for this other malignancy within 2 years is less than 10%, as determined by an expert in that particular malignancy at MD Anderson Cancer Center, and after consultation with the Principal Investigator.\n\n17\\. History of allergic reactions attributed to compounds of similar chemical or biological composition to sonrotoclax or BGB-16673 or other agents used in this study.\n\n18\\. Malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drugs 19. Receipt of live-virus vaccines within 4 weeks prior to starting study drugs 20. History of bleeding diathesis and\u002For history of known bleeding disorder including hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention 21. History of ischemic stroke or intracranial hemorrhage within 6 months of the first dose of study drug 22. Known prolymphocytic leukemia or history of, or currently suspected, Richter transformation (biopsy based on clinical suspicion may be needed to rule our transformation) 23. Known history of central nervous system involvement by CLL 24. Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements 25. Patients who are receiving any other investigational agents.",{"count":205,"type":22},[90],"This is an open-label, single-arm, phase II study which will assess the safety and efficacy of BGB16673 in combination with sonrotoclax as a time-limited approach for participants with treatment-naive CLL\u002FSLL.",[26],"2026-03-30",{"date":440,"type":40},"2026-04-03",{"date":442,"type":22},"2026-09-01",{"date":444,"type":22},"2033-07-01",{"name":446,"class":232},"M.D. Anderson Cancer Center",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":88,"phases":456,"briefSummary":457,"conditions":458,"keywords":459,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":472},"100426218","phase-1-a-study-of-nx-2127-in-adults-with-relapsedrefractory-b-cell-malignancies-100426218","NCT04830137","A Study of NX-2127 in Adults With Relapsed\u002FRefractory B-cell Malignancies","A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed\u002FRefractory B-cell Malignancies","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age\n* Patients must have measurable disease per disease-specific response criteria\n* Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, or International PCNSL Collaborative Group response criteria)\n* Patients with transformed lymphoma are eligible for the study with the exception of those detailed in Exclusion Criteria #1: Prolymphocytic leukemia, MCL with blastoid histology, MCL with pleomorphic morphology, or MCL with known TP53 mutation\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (non-PCNSL indications) or 0 - 2 (PCNSL patients)\n* Adequate organ and bone marrow function\n* Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol\n\nInclusion Criteria for Patients in Phase 1a:\n\n* Have histologically confirmed R\u002FR CLL, SLL, WM, MCL, and MZL, FL, DLBCL, or PCNSL\n* Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit\n* Must require systemic therapy\n\nInclusion Criteria for Patients in Phase 1b:\n\n* Must have one of the following histologically documented R\u002FR B-cell malignancies:\n\n  * CLL\u002FSLL whose disease has failed treatment with a BTKi;\n  * MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen\n  * FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTKi\n  * PCNSL whose disease failed at least 1 prior line of treatment\n  * DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another\u002F palliative regimen (either progressed post stem cell transplant or transplant-ineligible)\n\nExclusion Criteria:\n\n* Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia\n* History of known\u002Fsuspected other autoimmune disease (exception(s): patients with alopecia, vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.)\n* Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug\n* Bleeding diathesis, or other known risk for acute blood loss\n* Patients requiring ongoing treatment with warfarin or an equivalent vitamin K antagonist and within 7 days prior to the first dose of study drug\n* Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)\n* Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).\n* Active known second malignancy. Exception: patients with non-metastatic, non-melanoma skin cancer are eligible\n* Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug\n* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., CD4 \\> 350\u002Fmm3 and undetectable viral load) are eligible.\n* Current active liver disease from any cause\n* Active viral reactivation (e.g., CMV or EBV)\n* Use of systemic corticosteroids exceeding 20 mg\u002Fday prednisone (or equivalent) for non-PCNSL indications within 15 days prior to the planned start of study drug. PCNSL patients may not exceed corticosteroid doses of 40 mg\u002Fday prednisone (or equivalent) and should be on a stable or decreasing dose for 7 days prior to planned study start.\n* Use of non-steroidal immunosuppressive drugs within 30 days prior to start of the study\n* Clinically significant, uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug\n* Administration of any strong cytochrome P450 3A (CYP3A) inducers or inhibitors for 14 days prior to the first dose of study drug, and any P-glycoprotein inhibitors (for 2 days) or moderate inducers of CYP3A for 7 days",{"count":455,"type":22},248,[179],"This is a first-in-human Phase 1a\u002F1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.",[26,93,183,64,65,63,62,184],[151,152,154,155,460,461,462,156,463,158,159,188,189],"IMiD","Lenalidomide","Pomalidomide","NX-2127","2026-03-18",{"date":466,"type":40},"2026-03-20",{"date":468,"type":40},"2021-05-05",{"date":470,"type":22},"2027-05",{"name":167,"class":47},16,{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":88,"phases":482,"briefSummary":483,"conditions":484,"keywords":491,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":76},"100376822","phase-1-car-2019-t-cells-in-patients-with-relapsed-refractory-b-cell-malignancies-100376822","NCT04186520","CAR-20\u002F19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","Phase I\u002FII Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and\u002For Refractory B Cell Malignancies","GENERAL INCLUSION CRITERIA FOR ALL PATIENTS\n\n1. Patients must be aged ≥18 years and ≤80 years with relapsed or refractory B-cell non-Hodgkin Lymphoma.\n2. Absolute cluster of differentiation 3 (CD3) count ≥50 mm\\^3.\n3. Magnetic resonance imaging (MRI) brain and lumbar puncture with cerebrospinal fluid (CSF) analysis by cytology and flow cytometry without evidence of central nervous system (CNS) involvement ONLY in patients with history of CNS involvement or clinical suspicion at the time of enrollment EXCEPT Arm E subjects.\n4. Measurable disease must be documented within four weeks of the time of consent defined as nodal lesions greater than 15 mm in the long axis or extranodal lesions \\>10 mm in long and short axis OR bone marrow involvement that is biopsy proven for B-cell NHL (see separate criteria for CLL and primary\u002Fsecondary CNS lymphoma).\n5. Karnofsky performance score ≥70.\n6. Adequate hepatic function, defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C5 x upper limit of normal (ULN); serum bilirubin and alkaline phosphatase \\\u003C5 x ULN, or considered not clinically significant as per the clinical PIs discretion (e.g. Gilbert's or indirect hyperbilirubinemia) or felt to be due to underlying disease.\n7. ANC≥1000 with no G-CSF within 72 hours or pegylated G-CSF within 14 days.\n8. Platelets≥50,000 with no transfusion within 72 hours.\n9. Adequate renal function, defined as creatinine clearance \\>60 ml\u002Fmin AND serum Cr≤1.5 mg\u002FdL.\n\n   a. No IV hydration within 24 hours of eligibility. b. No dialysis dependent renal failure within three months of planned CAR infusion.\n10. Able to provide written informed consent.\n11. Agree to practice birth control during the study.\n12. Adequate cardiac function as indicated by New York Heart Association (NYHA) classification I or II AND left ventricular ejection fraction of ≥45% (by cardiac echocardiogram (ECHO) or multigated acquisition scan (MUGA)) and adequate pulmonary function as indicated by room air oxygen saturation of ≥92%.\n13. Expected survival \\>12 weeks.\n14. Negative urine or serum pregnancy test in females of child bearing potential at study entry.\n15. Meet criteria regarding fertility and contraception.\n16. No contraindication to central line access.\n17. Patient has demonstrated compliance to other therapies.\n\nPhase 1: 3+3 COHORT ELEGIBILITY CRITERIA\n\n1. Diagnosis of B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), Mantle Cell Lymphoma, and DLBCL with associated subtypes (aggressive B-cell lymphoma, high grade B-cell lymphoma, T-cell\u002Fhistocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, Epstein-Barr virus-positive (EBV+) diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).\n2. Patients must have active, measurable disease as defined and meet one of the following criteria.\n\n   1. Must have received Rituximab or another cluster of differentiation 20 (CD20) antibody and at minimum two different chemotherapy regimens appropriate for their disease and be ineligible to receive autologous transplant.\n   2. Relapse post-autologous transplant\n   3. Relapse post-allogeneic transplant\n   4. Patients not previously treated with CAR-T cell therapy\n\nPHASE 1b and 2 COHORT ELEGIBILITY CRITERIA\n\nARM A: Six to nine patient expansion with 8-day manufacturing (Phase 1b)\n\n1. Diagnosis of B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), and DLBCL with associated subtypes (aggressive B-cell lymphoma, T-cell\u002Fhistocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, EBV+ diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).\n2. Patients must have active, measurable disease as defined and meet one of the following criteria:\n\n   1. Must have received Rituximab or another cluster of differentiation 20 (CD20) antibody and at minimum two different chemotherapy regimens appropriate for their disease and be ineligible to receive autologous transplant.\n   2. Relapse post-autologous transplant.\n   3. Relapse post-allogeneic transplant.\n   4. Relapse post-anti-cluster of differentiation 19 (CD19) CAR-T cell therapy.\n\n   i. A maximum of two patients with prior CAR-T will be allowed in this cohort.\n\nARM B: Six to nine patient expansion with 12-day manufacturing (Phase 1b)\n\n1\\. Diagnosis of B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), and DLBCL with associated subtypes (aggressive B-cell lymphoma, high grade B-cell lymphoma, T-cell\u002Fhistocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, EBV+ diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).\n\n2\\. Patients must have active, measurable disease as defined and meet one of the following criteria:\n\n1. Must have received Rituximab or another CD20 antibody and at minimum two different chemotherapy regimens appropriate for their disease and be ineligible to receive autologous transplant.\n2. Relapse post-autologous transplant.\n3. Relapse post-allogeneic transplant.\n4. Relapse post-anti-CD19 CAR-T cell therapy.\n\ni. A maximum of two patients with prior CAR-T will be allowed in this cohort.\n\nARM C: 24 patient cryopreservation 8\u002F12 flexible manufacturing arm\n\n1. Diagnosis of B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), and DLBCL with associated subtypes (aggressive B-cell lymphoma, high grade B-cell lymphoma, T-cell\u002Fhistocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, EBV+ diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).\n2. Patients must have active, measurable disease as defined and meet one of the following criteria a. Must have received Rituximab or another CD20 antibody and at minimum two different chemotherapy regimens appropriate for their disease and be ineligible to receive autologous transplant b. Relapse post-autologous transplant c. Relapse post-allogeneic transplant d. Relapse post-anti-CD19 CAR-T cell therapy i. A maximum of 2 patients with prior CAR-T will be allowed in this cohort\n\nARM D: Phase 1 and Phase 1b: CLL\n\n1\\. Diagnosis of B-cell CLL or small lymphocytic leukemia (SLL) 2. Failed\u002Fprogressed or been intolerant to two prior lines of therapy one of which MUST be either a covalent BTK inhibitor (e.g. ibrutinib, acalabrutinib, zanabrutinib, etc) or BCL2 inhibitors (e.g. venetoclax or other investigational BCL2) 3. Indication for treatment as defined as any of the following:\n\n1. measurable lymph nodes ≥ 1.5 cm in the greatest transverse diameter and\u002For hepatomegaly or splenomegaly)\n2. bone marrow involvement with ≥10% CLL involvement\n\nARM E: Phase 1 and Phase1b Relapsed\u002FRefractory Primary or Secondary CNS Lymphoma\n\n1. Diagnosis of diffuse large B cell lymphoma (DLBCL) with associated subtypes (aggressive B-cell lymphoma, high grade B-cell lymphoma, T-cell\u002Fhistocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, EBV+ diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation) with secondary CNS lymphoma involvement OR primary CNS lymphoma.\n2. For Primary CNS lymphoma, relapsed or refractory following at least one line of CNS-directed therapy.\n3. Secondary CNS lymphoma relapsed or refractory following at least one line of CNS-directed therapy for treatment of CNS lymphoma.\n\n   1. For patients with secondary central nervous system lymphoma (CNSL) with concurrent systemic lymphoma, the concurrent systemic lymphoma must have relapsed following at least 1 prior line of therapy (which must have included an anti-CD20 monoclonal antibody and an anthracycline)\n4. Measurable CNS disease by either lumbar puncture (LP) with positivity in CNS by flow cytometry or morphology for lymphoma cells OR magnetic resonance imaging (MRI) with enhancing lesions ≥1 cm in size consistent with lymphoma\n5. Must have had prior treatment with high dose methotrexate defined as methotrexate given intravenously at a dose ≥2500 mg\u002Fm\\^2 and either progression\u002Frelapse, stable disease, or intolerance to at least one cycle of treatment.\n\nPhase II Cohort: Mantle Cell Lymphoma\n\n1\\. Diagnosis of Mantle Cell Lymphoma. 2. Patients must have active, measurable disease as previously defined and have relapsed, refractory disease as defined as one of the following:\n\n1. Relapsed disease after two lines of cytotoxic chemotherapy including administration of anti-CD20 antibody.\n2. Progressive disease after ≥second line Bruton tyrosine kinase (BTK) inhibitor.\n3. Relapse post-autologous transplant.\n4. Relapse post-allogeneic transplant.\n5. Relapse post anti-CD19 CAR-T cell therapy.\n\ni. A maximum of four patients with history of prior anti-CD19 CAR-T will be allowed in this cohort.\n\nEXCLUSION CRITERIA (ALL PATIENTS)\n\nA potential subject who meets any of the following exclusion criteria is ineligible to participate in the study.\n\n1. Positive beta- human chorionic gonadotropin (HCG) in female of childbearing potential.\n2. Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.\n3. History of significant autoimmune disease OR active, uncontrolled autoimmune phenomenon requiring steroid therapy defined as \\>20 mg of prednisone or equivalent daily.\n4. Presence of ≥grade 3 non-hematologic toxicities as per CTCAE version 5.0 from any previous treatment unless it is felt to be due to underlying disease.\n5. Concurrent use of investigational therapeutic agents or enrollment on another therapeutic clinical trial at any institution. Minimum of 14 days or 5 half-lives of the drug (whichever is shorter) washout prior to apheresis.\n6. Refusal to participate in the long-term follow-up protocol\n7. Patients with active CNS involvement by malignancy on MRI or by lumbar puncture (Not applicable to Arm E cohort.)\n\n   a. Patients with prior CNS disease that has been effectively treated will be eligible providing treatment was \\>4 weeks before enrollment and a remission documented within 8 weeks of planned CAR-T cell infusion by MRI brain and CSF analysis.\n8. Previous recipients of allogeneic hematopoietic stem cell transplantation (AHCT) are excluded if they are \\\u003C100 days' post-transplant, have evidence of active graft-versus-host-disease (GVHD) of any grade, or are currently on immunosuppression.\n9. Prior allogeneic CAR T-cell therapy\n10. Previous recipients of autologous CAR-T cell therapy directed at either CD19 or CD20 are excluded if they are \\\u003C100 days post prior CAR-T cell treatment (does not include re-enrollment) or have \\>5% residual circulating CAR-T as measured by flow cytometry using a CD19 CAR detection reagent (Miltenyi Biotec)\n\n    a. Patients with prior CAR-T treatment against CD19 or CD20 must have repeat biopsy post-CAR-T cell therapy confirming a minimum of 5% CD19 or CD20 positivity by immunohistochemistry or flow cytometry\n11. Anti-CD20 antibody treatment within 4 weeks of cell infusion\n12. Anti-CD19 antibody treatment within 4 weeks of cell infusion\n13. Cytotoxic chemotherapy other than lymphodepletion within 14 days of CAR-T cell infusion\n14. Cytotoxic chemotherapy treatment within 14 days or steroid treatment (other than replacement dose steroids) within 7 days prior to apheresis collection for CAR-T cells\n15. Oral chemotherapeutic agents or antibody directed treatment within 7 days of apheresis\n\n    a. BTK inhibitors are allowed until 1-day prior to apheresis and can re-start until 1-day prior to lymphodepletion\n16. Patients post solid organ transplant who develop high grade lymphomas or leukemias\n17. Concurrent active malignancy other than basal or squamous cell carcinomas of the skin (underlying low-grade lymphoma chronic lymphocytic leukemia\u002Ffollicular lymphoma (FL)\u002Fmarginal zone lymphoma (MZL) is allowable in patients with transformed large cell lymphoma)\n\nSPECIAL CRITERIA REGARDING FERTILITY AND CONTRACEPTION\n\nFemale subjects of reproductive potential (women who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or have not undergone a sterilization procedure \\[hysterectomy or bilateral oophorectomy\\]) must have a negative serum or urine pregnancy test performed as part of eligibility criteria Due to the high-risk level of this study, while enrolled, all subjects must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). Additionally, if participating in sexual activity that could lead to pregnancy, the study subject must agree to use reliable and double barrier methods of contraception during the follow-up period of the protocol.\n\nAcceptable birth control includes a combination of two of the following methods:\n\n* Condoms (male or female) with or without a spermicidal agent.\n* Diaphragm or cervical cap with spermicide\n* Intrauterine device (IUD)\n* Hormonal-based contraception Subjects who are not of reproductive potential (women who are premenarche or have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy tubal ligation, salpingectomy, and\u002For bilateral oophorectomy or men who have documented azoospermia) are eligible without requiring the use of contraception","80 Years",{"count":146,"type":22},[179,90],"This is a Phase I\u002FII, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7\u002FIL-15) manufactured chimeric antigen receptor (CAR)-20\u002F19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.",[485,64,26,486,487,488,489,490],"Non Hodgkin Lymphoma (NHL)","Follicular Lymphoma","Marginal Zone Lymphoma","Diffuse Large B Cell Lymphoma","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Central Nervous System Lymphoma",[492,493,494,495],"CAR-T","Chimeric antigen receptor T-cell therapy","CAR Therapy","B-cell Malignancies","2026-02-19",{"date":498,"type":40},"2026-02-23",{"date":500,"type":40},"2020-05-18",{"date":253,"type":22},{"name":503,"class":232},"Medical College of Wisconsin",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":88,"phases":514,"briefSummary":515,"conditions":516,"keywords":517,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":530},"100431234","phase-2-study-to-assess-change-in-disease-activity-and-adverse-events-of-oral-venetoclax-with-intravenous-iv-obinutuzumab-in-adult-participants-with-recurring-chronic-lymphocytic-leukemia-cll-100431234","NCT04895436","Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia","ReVenG","Inclusion Criteria:\n\n* Documented diagnosis of chronic lymphocytic leukemia (CLL) that requires treatment for CLL according to International Workshop for Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria.\n* Previously completed venetoclax + anti-CD20 antibody +\u002F- X regimen as a fixed duration first-line (1L) therapy and achieved documented response, defined as complete remission, complete remission with incomplete marrow recovery, partial remission, or nodular partial remission.\n* More than 24 months (Cohort 1) or 12-24 months (Cohort 2) have elapsed between last dose of venetoclax and disease progression after completion of 1L treatment.\n\nExclusion Criteria:\n\n\\- Received intervening treatment for CLL after completing previous treatment with a venetoclax + anti-CD20 antibody +\u002F- X regimen.",{"count":513,"type":22},75,[90],"Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +\u002F- X (where X is any additional drug). Adverse events and change in disease activity will be assessed.\n\nVenetoclax is an approved drug for the treatment of CLL. Study doctors put the participants in 1 of 2 groups, called cohorts, based on when symptoms of CLL came back after previous treatment in first-line. Approximately 75 adult participants with CLL who have been treated with venetoclax in combination with an anti-CD20 antibody +\u002F- X will be enrolled in the study in approximately 60 sites worldwide.\n\nParticipants will receive intravenous (IV) obinutuzumab + oral venetoclax (VenG) in 28-day cycles for a total of 6 cycles per cohort, followed by 6 to 18 cycles of venetoclax alone, for a total treatment of 12 to 24 cycles, depending on the cohort.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[26],[26,398,33,518,519,397,520,521,28,510],"Venclexta","GDC-0199","Gazyva","GA101","2026-02-05",{"date":524,"type":40},"2026-02-09",{"date":526,"type":40},"2022-03-28",{"date":528,"type":22},"2029-01",{"name":46,"class":47},58,{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":537,"phases":4,"briefSummary":538,"conditions":539,"keywords":546,"overallStatus":553,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":557,"locationsCount":4},"100295215","expanded-access-to-venetoclax-100295215","NCT03123029","Expanded Access to Venetoclax","Exclusion Criteria:\n\n* There are other suitable treatment options.\n* The participant qualifies for ongoing clinical trials.","EXPANDED_ACCESS","This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.",[26,540,541,542,543,544,545],"Multiple Myeloma","Acute Myeloid Leukemia (AML)","Non-Hodgkin's Lymphoma","Acute Lymphoblastic Leukemia (ALL)","Amyloidosis","Plasma Cell Leukemia",[547,548,549,550,551,552],"Expanded Access","Pre-approval Access","Compassionate Use","Special Access Program","Named Patient Basis","Special Access Scheme","AVAILABLE","2026-01-29",{"date":556,"type":40},"2026-01-30",{"name":46,"class":47},{"id":559,"slug":4,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":560,"targetDuration":59,"studyType":23,"phases":4,"briefSummary":60,"conditions":561,"keywords":562,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":567,"leadSponsor":568,"locationsCount":76},"100519397",{"count":58,"type":22},[26,62,63,64,65,66],[68],"2026-01-26",{"date":565,"type":40},"2026-01-28",{"date":71,"type":40},{"date":73,"type":22},{"name":75,"class":47},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":88,"phases":578,"briefSummary":579,"conditions":580,"keywords":581,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":594},"100283222","phase-2-a-study-of-venetoclax-in-participants-with-relapsed-or-refractory-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-100283222","NCT02966756","A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Inclusion Criteria:\n\n* Participant must have a diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL) that meets 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (iwCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines and the following:\n\n  * Participant must have an indication for treatment according to the 2008 Modified iwCLL NCI-WG Guidelines.\n  * SLL participant must have measurable disease (B-lymphocytosis greater than 5 × 10\\^9\u002FL or an enlarged lymph node(s) (Longest Diameter (LDi) \\> 1.5 cm at baseline) or hepatomegaly or splenomegaly due to CLL).\n  * SLL participant must have presence of lymphadenopathy and absence of cytopenias caused by a clonal marrow infiltrate.\n  * Participant must have relapsed or refractory CLL\u002FSLL after receiving at least one prior line of therapy.\n* Participants (in Cohort 1) must have 17p deletion, assessed by a central laboratory.\n* Participants (in Cohort 2) must meet both of the following:\n\n  * Relapsed\u002Frefractory disease to B-Cell Receptor Signaling Pathway Inhibitor (BCRI) treatment;\n  * And either of the following: (a) relapsed\u002Frefractory disease to chemoimmunotherapy (CIT), or (b) ineligible to receive CIT, defined as having known 17p deletion or TP53 mutation, or Cumulative Illness Rating Scale (CIRS) \\>6 or calculated creatinine clearance \\\u003C70 mL\u002Fmin, or participants in whom the investigator evaluated that the use of CIT was inappropriate.\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.\n* Participant must have adequate bone marrow function, coagulation profile, renal, and hepatic function, per laboratory reference range at Screening.\n* No known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\n\nExclusion Criteria:\n\n* Participant has undergone an allogeneic stem cell transplant.\n* Participant has developed Richter's transformation confirmed by biopsy.\n* Participant has prolymphocytic leukemia.\n* Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to screening), including autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura (ITP).\n* Participant has previously received venetoclax or other BCL-2 inhibitors.\n* Participant is known to be positive for Human Immunodeficiency Virus (HIV).\n* Participant has received a biologic agent for anti-neoplastic intent within 30 days prior to the first dose of study drug.\n* Participant has received any of the following within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of venetoclax, or has not recovered to less than Common Toxicity Criteria for Adverse Events (CTCAE) grade 2 clinically significant adverse effect(s)\u002Ftoxicity(s) of the previous therapy:\n\n  * Any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy or targeted small molecule agents.\n  * Investigational therapy, including targeted small molecule agents.\n* Participant has known allergy to both xanthine oxidase inhibitors and rasburicase.",{"count":577,"type":22},110,[90],"This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2).",[26,93],[582,583,584,398,29,585,93,518],"Relapsed chronic lymphocytic leukemia (CLL)","Refractory chronic lymphocytic leukemia (CLL)","17p deletion","Lymphoproliferative Disorders","2025-12-18",{"date":588,"type":40},"2025-12-24",{"date":590,"type":40},"2017-10-12",{"date":592,"type":22},"2029-05",{"name":46,"class":47},31,{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":88,"phases":604,"briefSummary":605,"conditions":606,"keywords":611,"overallStatus":223,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":618,"leadSponsor":620,"locationsCount":4},"100614972","precision-physical-exercise-for-personalized-onco-hematology-100614972","NCT07286539","Precision Physical Exercise for Personalized Onco-Hematology.","PEPOH","Inclusión criteria:\n\n* Adult patients (≥18 years), capable of signing the informed consent and willing to participate in the study.\n* Performance status (ECOG) 0-2.\n* Specific inclusion criteria are defined for each cohort involved in the study as follows:\n\nLung cancer: Patients diagnosed with non-small cell lung carcinoma in metastatic stage, eligible for combined immunotherapy and chemotherapy, with active treatment.\n\nColorectal cancer: Patients with stage II, III, or IV resected colorectal cancer undergoing adjuvant chemotherapy.\n\nBreast cancer: Female patients with histologically confirmed hormone receptor-positive\u002FHER2-negative breast cancer, receiving active hormonal therapy (tamoxifen, aromatase inhibitor, or fulvestrant) in either adjuvant or stable metastatic phase.\n\nChronic lymphocytic leukemia (CLL): Patients diagnosed with CLL who have not received and are not in need of pharmacological treatment.\n\nMultiple myeloma (MM): Patients with a confirmed new diagnosis of MM under active first line treatment and non-candidates to autologous transplantation.\n\nExclusion criteria:\n\n* Presence of unstable bone metastases or extensive bone involvement associated with a high risk of fracture.\n* Uncontrolled cardiovascular, respiratory, musculoskeletal, or metabolic diseases that contraindicate physical exercise at the investigator's discretion.\n* Explicit medical contraindication to exercise training.\n* Documented poor adherence (\\\u003C80%).\n* Treatment discontinuation, disease progression, intolerance, or any other medical, personal, or logistical circumstance that, in the opinion of the investigators, may compromise participant safety or the integrity of the study.",{"count":603,"type":22},150,[207],"Physical exercise, particularly strength training, has become an effective strategy to improve physical function, muscle mass, and quality of life in cancer patients. However, the biological mechanisms underlying these benefits remain poorly understood, especially during active treatment. The PEPOH project (Precision physical Exercise for Personalized Onco-Hematology) proposes a single-center clinical trial conducted at the Fundación del Instituto de Investigación Biomédica de Salamanca (FIBSAL) including five different patient cohorts: lung, colorectal (CRC), and breast cancer, chronic lymphocytic leukemia, and multiple myeloma. Participants will be randomly assigned to either an in-person intervention group, performing a supervised strength training program twice a week for 12 weeks combined with a home-based exercise program, or a control group performing only the home-based program. Biological samples will be collected before and after the intervention for multi-dimensional characterization (Genomics, Transcriptomics, Proteomics and Metabolomics) and systematic integration with parameters of functional capacity, quality of life, psychological well-being, frailty, and body composition. The main objective of the project is to determine biological parameters associated with strength exercise and their relationship with clinical parameters related to prognosis, therapy response and survival. This multi-dimensional approach will enable the detection of exercise adaptation biomarkers and generate knowledge about the mechanisms linking exercise with improved health outcomes in individuals with cancer. PEPOH will contribute to biomedical science and will enhance the comprehensive care of oncohematologic patients by integrating multi-omic and clinical data into a precision exercise model. This project will also contribute to society by offering a cost-effective, safe, and transferable intervention, which increases the overall quality of life.",[607,608,609,155,26,610],"Hematologic Cancer","Colon Cancer","Breast Cancer","Lung Cancer",[612,28,613],"Exercise","Well-being","2025-12-12",{"date":616,"type":40},"2025-12-16",{"date":421,"type":22},{"date":619,"type":22},"2030-12-31",{"name":621,"class":232},"University of Salamanca",{"id":623,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":624,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":625,"keywords":626,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":631,"leadSponsor":632,"locationsCount":48},"100312030",{"count":21,"type":22},[26],[26,28,29,30,31,32,33,34,35],"2025-12-02",{"date":629,"type":40},"2025-12-08",{"date":42,"type":40},{"date":44,"type":22},{"name":46,"class":47},{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":4,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":88,"phases":642,"briefSummary":643,"conditions":644,"keywords":645,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":655},"100452240","phase-2-zanubrutinib-and-venetoclax-in-cll-zanu-ven-100452240","NCT05168930","Zanubrutinib and Venetoclax in CLL (ZANU-VEN)","A Phase 2 Trial of Zanubrutinib and Venetoclax in Previously Treated CLL\u002FSLL Patients","Inclusion Criteria\n\n* Confirmed diagnosis of CLL or SLL as per 2018 International Workshop on CLL (IWCLL) criteria.\n* Participants must have relapsed after at least one prior line of therapy and must currently require therapy by 2019 IWCLL criteria.\n* For enrollment to Cohort A: Participants must be covalent BTK and BCL-2 inhibitor naïve. Participants who have received prior therapy with a covalent BTK or BCL-2 inhibitor are not eligible, including but not limited to prior treatment with ibrutinib or acalabrutinib.\n* For enrollment to Cohort B: Participants must have had prior treatment with a BTK inhibitor or a BCL-2 inhibitor, but not both, and must not have experienced disease progression as defined by iwCLL criteria while receiving therapy.\n* For enrollment to Cohort C: participants must have a disease that progressed during therapy with a covalent BTK inhibitor, not including zanubrutinib.\n* Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of zanubrutinib and venetoclax in participants \\\u003C 18 years of age and CLL\u002FSLL is extremely rare in this population, children are excluded from this study.\n* ECOG performance status ≤ 2 (Karnofsky ≥ 60%, see Appendix A).\n* Participants must have adequate organ function as defined below:\n\n  * Platelet count ≥ 20,000\u002FmcL\n  * Total bilirubin ≤ 2 × institutional upper limit of normal (ULN) (unless due to controlled hemolysis, Gilbert's disease, or is of non-hepatic origin)\n  * AST (SGOT) and ALT (SGPT) ≤ 4 × institutional ULN\n  * Serum Creatinine ≤ 1.5 × institutional ULN, OR\n  * Calculated creatinine clearance ≥ 50 mL\u002Fmin (as calculated by the Cockcroft-Gault formula)\n* The effects of zanubrutinib or venetoclax on the developing human fetus are unknown. For this reason and because anti-cancer agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study agent administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n* Ability to swallow and retain oral medication.\n\nExclusion Criteria:\n\n* Known BTK C481X mutation.\n* For enrollment to Cohort B: participants who have received prior treatment with both a BTK inhibitor and BCL-2 inhibitor.\n* Participants who have had previous anti-cancer therapy (e.g., chemotherapy, radiotherapy, immunotherapy, biologic therapy, hormonal therapy, surgery, investigational agents, and\u002For tumor embolization) within 2 weeks of Cycle 1 Day 1 with the following exceptions:\n* Hormonal therapy given in the adjuvant setting\n* Corticosteroid therapy (prednisone or equivalent ≤ 20 mg daily) is allowed as clinically warranted as long as the dose is stabilized at least for 7 days prior to initial dosing. Topical, inhaled, intra-articular, or ophthalmologic corticosteroids are permitted\n* Participants enrolling to Cohort C may remain on prior BTK inhibitor therapy up until 2 days prior to Cycle 1 Day 1\n* History of a prior allogeneic hematologic stem cell transplant.\n* Participants with known central nervous system (CNS) involvement, because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Participants with no known history of CNS involvement are not required to undergo CT scan or lumbar puncture (LP) for trial eligibility unless the participant is symptomatic as judged by the treating investigator.\n* Participants who are receiving any other investigational agents at the time of study entry.\n* History of other malignancies, with the following exceptions:\n\n  * Malignancy treated with curative intent and with no known active disease present for ≥ 2 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n  * Adequately treated carcinoma in situ without evidence of disease\n  * Low-risk prostate cancer on active surveillance\n* Participants who have been vaccinated with live, attenuated vaccines \\\u003C 4 weeks prior to Cycle 1 Day 1.\n* Recent infection requiring intravenous antibiotics completed ≤ 7 days before the first dose of study drug, or any uncontrolled active systemic infection.\n* Known bleeding disorders (e.g. von Willebrand's disease) or hemophilia.\n* History of stroke, intracranial hemorrhage, or recent major bleed within 6 months prior to study entry.\n* Participants who require warfarin or other vitamin K antagonists for anticoagulation (other anticoagulants are allowed with approval from the overall principal investigator).\n* Participants who are known at the time of study entry to require concomitant treatment with any medications or substances that are moderate or strong CYP3A inhibitors or inducers. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\u002Finformed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.\n* Known history of human immunodeficiency virus (HIV), active hepatitis C virus (HCV), or hepatitis B virus (HBV).\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to zanubrutinib or venetoclax.\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because zanubrutinib and venetoclax are anti-cancer agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with zanubrutinib or venetoclax, breastfeeding should be discontinued if the mother is treated with zanubrutinib or venetoclax.\n* Participants with malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.\n* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to study entry.\n* Any life-threatening illness, medical condition, or organ system dysfunction that, in the treating investigator's opinion, could compromise the participant's safety or the integrity of the trial.\n* Active and\u002For ongoing autoimmune anemia and\u002For autoimmune thrombocytopenia.",{"count":641,"type":22},45,[90],"This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",[26,93],[396,398],"2025-12-01",{"date":648,"type":40},"2025-12-05",{"date":650,"type":40},"2022-02-18",{"date":652,"type":22},"2028-10-28",{"name":654,"class":232},"Dana-Farber Cancer Institute",4]